Bailly Creat owner Patrick Choay donates pharmaceutical products to the Samdech Techo Voluntary Youth Doctor Association (TYDA). SUPPLIED
French pharmaceutical innovator Bailly Creat – which has been distributing its products in the Kingdom for nearly four decades – is expanding its market by introducing more of its medicines to Cambodia.
Bailly Creat on October 26 launched its Ibuprofen, Desloratadine, and Amoxicillin + Clavulanic Acid products in the Kingdom through its distribution partner Zuellig Pharma, one of the largest healthcare services groups in Asia.
Patrick Choay – the CEO of the Patrick Choay Group, which has owned Bailly Creat since 1996 – launched the new products and donated medicine to the Cambodian Red Cross and the Samdech Techo Voluntary Youth Doctor Association (TYDA).
“Bailly-Creat has been marketing a wide range of products in Cambodia for more than 40 years, medicines that respect European quality standards.
“We are honoured to be able to enrich our offer with the products we present to you today. These new medicines are now available at Zuellig Pharma to meet your prescription needs, and for dispensing in pharmacies.
“We are optimistic that our collaboration with Zuellig Pharma will be long-lasting and a prolific one, not just for us, but also for the people of Cambodia,” Choay said at the launch ceremony.
The Patrick Choay Group, an independent French pharmaceutical group, also owns Laboratoire CCD, which has been at the core of women’s health for 50 years, and Laboratoire du Gomenol, which manufactures and produces cosmetics and food supplements.
The Cambodian Red Cross receives medicines from Patrick Chaoy. SUPPLIED
It also owns Prodimed, which designs and manufactures disposable medical and surgical equipment.
With a workforce of some 300 employees, it actively promotes its medicines globally.
Laboratory Bailly can trace its roots back to 1901, while Laboratory Creat was formed in 1972. The two merged in 2002.
Bailly Creat is known for its expertise in the formulation, manufacture and production of oral solid drug products and food supplements in dry form.
Backed by strong research and development programmes, Bailly Creat produces and distributes its generic products in more than 30 countries.
In Cambodia, the company has been marketing a wide range of medicines that meet European quality standards.
With these medicines used in the Kingdom, the company said it believed it appropriate to return the favour by means of the donation initiatives, which will help many Cambodians treat illnesses with medicines scientifically proven to be effective.
Bailly Creat launch the products in Phnom Penh on October 26. SUPPLIED
